Streetbeat News

Analyst Ratings

ABBV

TAK

Takeda Pharmaceutical's (TAK) Phase 3 ADMIRE-CD II study for Alofisel, a treatment for complex Crohn's Perianal Fistulas, did not meet its primary endpoint. The company also settled a tax dispute with the Irish Revenue Commissioners related to a break fee received by Shire plc from AbbVie (ABBV) in 2014. Takeda's shares fell 1.47% in premarket trading.

Portfolio Pulse from Vandana Singh

October 18, 2023 | 12:25 pm

BKR

Barclays analyst David Anderson maintains an Overweight rating on Baker Hughes (NASDAQ:BKR) but lowers the price target from $43 to $42.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:23 pm

ALB

B of A Securities analyst Matthew DeYoe has downgraded Albemarle (NYSE:ALB) from Neutral to Underperform and lowered the price target from $212 to $161.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:22 pm

COST

CVS

MDLZ

SHEL

On CNBC's 'Halftime Report Final Trades', Brenda Vingiello of Sand Hill Global Advisors praised Mondelez International's organic growth. Analysts from Exane BNP Paribas and BofA Securities have upgraded and maintained the stock respectively, though the latter lowered the price target. CVS Health Corporation was named as a final trade by Jim Lebenthal of Cerity Partners, despite reports of a planned nationwide walkout by pharmacy staff. Amy Raskin of Chevy Chase Trust highlighted Shell's cheap stock and nice dividend, and the company's expanded collaboration with C3.ai. Joseph Terranova of Virtus Investment Partners mentioned Costco Wholesale Corporation, which is facing legal action over sharing sensitive customer information.

Portfolio Pulse from Lisa Levin

October 18, 2023 | 12:20 pm

WLK

B of A Securities analyst Steve Byrne has downgraded Westlake (NYSE:WLK) from Neutral to Underperform and lowered the price target from $142 to $129.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:18 pm

BIP

National Bank Financial Inc's analyst Patrick Kenny has upgraded Brookfield Infrastructure Partners (NYSE:BIP) from Sector Perform to Outperform.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:15 pm

GTHX

The American Society of Clinical Oncology has updated its guidelines for small cell lung cancer to include G1 Therapeutics' COSELA. This recommendation could potentially increase the usage of COSELA, benefiting G1 Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:15 pm

LMT

Citigroup analyst Jason Gursky maintains a Buy rating on Lockheed Martin (NYSE:LMT) but has lowered the price target from $555 to $540.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:13 pm

CBAY

CymaBay Therapeutics (NASDAQ:CBAY) announced that results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD). Seladelpar is a potent, selective, orally active delpar or PPARδ agonist, in development for the treatment of adult patients with PBC. The company looks forward to sharing the results, which is an important step forward in obtaining regulatory review and potentially marketing authorization.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:13 pm

FBK

Janney Montgomery Scott analyst Feddie Stickland has upgraded FB Financial (NYSE:FBK) from Neutral to Buy and announced a price target of $35.5.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:13 pm